Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare Psychedelics
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

Accesswire June 18, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

Business Wire June 16, 2022

Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience

GlobeNewswire June 13, 2022

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2022

Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast

GlobeNewswire May 3, 2022

Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

GlobeNewswire April 25, 2022

Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

GlobeNewswire April 21, 2022

Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 5, 2022

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 1, 2022

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

GlobeNewswire February 22, 2022

Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire January 7, 2022

Intra-Cellular Therapies Prices Public Offering of Common Stock

GlobeNewswire January 4, 2022

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

GlobeNewswire January 3, 2022

Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2022

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

GlobeNewswire December 20, 2021

Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner

GlobeNewswire December 6, 2021

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2021

Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast

GlobeNewswire November 2, 2021

Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20

GlobeNewswire October 18, 2021